HomeCompareALGCF vs ABBV

ALGCF vs ABBV: Dividend Comparison 2026

ALGCF yields 25000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALGCF wins by $481652020747103174656.00M in total portfolio value
10 years
ALGCF
ALGCF
● Live price
25000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$481652020747103174656.00M
Annual income
$477,891,679,681,809,340,000,000,000.00
Full ALGCF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — ALGCF vs ABBV

📍 ALGCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALGCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALGCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALGCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALGCF
Annual income on $10K today (after 15% tax)
$2,125,000.00/yr
After 10yr DRIP, annual income (after tax)
$406,207,927,729,537,960,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ALGCF beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALGCF + ABBV for your $10,000?

ALGCF: 50%ABBV: 50%
100% ABBV50/50100% ALGCF
Portfolio after 10yr
$240826010373551587328.00M
Annual income
$238,945,839,840,904,670,000,000,000.00/yr
Blended yield
99.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ALGCF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALGCF buys
0
ABBV buys
0
No recent congressional trades found for ALGCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALGCFABBV
Forward yield25000.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$481652020747103174656.00M$104.7K
Annual income after 10y$477,891,679,681,809,340,000,000,000.00$25,725.73
Total dividends collected$481404327977371041792.00M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ALGCF vs ABBV ($10,000, DRIP)

YearALGCF PortfolioALGCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,510,700$2,500,000.00$11,559$438.51+$2.50MALGCF
2$589,298,599$586,612,149.53$13,494$640.86+$589.29MALGCF
3$129,309,604,119$128,679,054,618.90$15,951$945.97+$129309.59MALGCF
4$26,527,150,102,459$26,388,788,826,051.22$19,152$1,413.89+$26527150.08MALGCF
5$5,087,743,001,217,608$5,059,358,950,607,977.00$23,443$2,146.38+$5087743001.19MALGCF
6$912,316,496,169,531,500$906,872,611,158,228,600.00$29,391$3,321.96+$912316496169.50MALGCF
7$152,954,929,371,424,950,000$151,978,750,720,523,570,000.00$37,948$5,265.87+$152954929371424.91MALGCF
8$23,976,822,470,935,107,000,000$23,813,160,696,507,682,000,000.00$50,795$8,596.74+$23976822470935108.00MALGCF
9$3,514,337,444,199,857,700,000,000$3,488,682,244,155,957,000,000,000.00$71,034$14,549.41+$3514337444199857664.00MALGCF
10$481,652,020,747,103,200,000,000,000$477,891,679,681,809,340,000,000,000.00$104,715$25,725.73+$481652020747103174656.00MALGCF

ALGCF vs ABBV: Complete Analysis 2026

ALGCFStock

Allegiance Coal Limited, together with its subsidiaries, engages in the acquisition, exploration, and development of coal tenements. It holds 100% equity interests in the New Elk metallurgical coal project located in Las Animas County in southeast Colorado; and Black Warrior coal mine situated in Alabama. The company also holds a 90% equity interest in the Telkwa metallurgical coal project located in British Columbia, Canada; Tenas Project situated in northwest British Columbia; and Short Creek mine assets located west of Birmingham, Alabama. Allegiance Coal Limited was incorporated in 2011 and is headquartered in Sydney, Australia.

Full ALGCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ALGCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALGCF vs SCHDALGCF vs JEPIALGCF vs OALGCF vs KOALGCF vs MAINALGCF vs JNJALGCF vs MRKALGCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.